Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADDERALL 10 vs DIPHENYLAN SODIUM
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.
Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
FDA-approved: Generalized tonic-clonic seizures, complex partial seizures,Off-label: Prevention of seizures during neurosurgery, status epilepticus (parenteral), trigeminal neuralgia
10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.
100 mg orally every 8 hours
Terminal elimination half-life: dextroamphetamine 9-11 hours, levoamphetamine 11-14 hours (Adderall is a mixed salt). In adults, mean half-life ~10 hours; in children, slightly shorter (6-8 hours). Clinical context: steady-state reached in 2-3 days; dosing interval typically 4-6 hours for immediate-release.
22 hours (range 10-34 hours); prolonged in hepatic impairment or with CYP inhibitors; correlates with time to steady state (~5 days).
Amphetamine is metabolized primarily in the liver via cytochrome P450 enzymes, including CYP2D6, and undergoes deamination and oxidation to form inactive metabolites including 4-hydroxyamphetamine and norephedrine.
Primarily hepatic metabolism via CYP2C9 and CYP2C19 isoenzymes, with saturation kinetics at therapeutic concentrations. Major metabolite: 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH).
Renal: 70-80% (30-40% as unchanged amphetamine; remainder as deaminated and hydroxylated metabolites). Fecal: minimal (<5%). Biliary: negligible. Urinary p H affects excretion: acidic urine increases elimination, alkaline urine decreases.
Primarily hepatic metabolism via CYP450; <5% excreted unchanged in urine. Biliary/fecal excretion accounts for approximately 20-30% of metabolites.
Amphetamine: 15-40% bound to plasma proteins (primarily albumin). Binding is not extensive, thus significant free fraction available for distribution.
90-95% mainly to albumin; displaces and is displaced by other highly protein-bound drugs.
Apparent Vd: 3.0-4.0 L/kg (for total amphetamine). High Vd indicates extensive tissue distribution, including brain. Clinical meaning: loading dose may be needed for rapid effect; distribution half-life ~1 hour.
0.6-0.8 L/kg; larger in neonates (up to 1.2 L/kg); indicates extensive tissue binding, particularly in brain and adipose.
Oral immediate-release: 100% (well-absorbed; first-pass metabolism minimal). Food delays absorption but does not affect extent. Extended-release: bioavailability similar to immediate-release with modified release profile.
Oral: 85-95% (capsules and tablets); intramuscular: 70-80% due to precipitation at injection site.
e GFR 15-29 m L/min: reduce dose by 50% and monitor for toxicity; e GFR <15 m L/min or dialysis: avoid use due to risk of accumulation; consider alternative therapy.
No adjustment required for GFR >30 m L/min; for GFR 10-30 m L/min, administer every 12-24 hours; for GFR <10 m L/min, administer every 24 hours with monitoring of serum levels
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use due to decreased clearance and increased risk of toxicity.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50%; Child-Pugh Class C: avoid use or reduce dose by 50-75% with close monitoring
Children 3-5 years: 2.5 mg orally once daily; may increase by 2.5 mg weekly; usual range 2.5-20 mg/day divided 1-2 times. Children 6 years and older: initial 5 mg once daily; may increase by 5 mg weekly; usual range 5-40 mg/day divided 1-3 times; maximum 40 mg/day.
5-7 mg/kg/day orally divided every 8-12 hours, not to exceed 300 mg/day
Initiate at 2.5-5 mg orally once daily; titrate slowly in increments of 2.5-5 mg weekly; monitor for cardiovascular effects, insomnia, and weight loss; maximum 40 mg/day.
Initial dose of 50 mg orally every 8 hours, titrate slowly based on response and tolerability; monitor renal function and serum levels
Potential for abuse and dependence. Amphetamines have a high potential for abuse, which may lead to dependence and serious cardiovascular adverse events. Misuse may cause sudden death and serious cardiovascular events.
Intravenous administration: Risk of serious cardiovascular reactions including hypotension and cardiac arrest, especially in elderly patients and those with underlying cardiac disease. Rate of infusion should not exceed 50 mg/min in adults.
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase; caution in hypertension and other cardiovascular conditions.,Psychiatric adverse events including exacerbation of psychosis, mania, and aggression.,Long-term suppression of growth in pediatric patients.,Peripheral vasculopathy including Raynaud's phenomenon.,Seizures: may lower seizure threshold.,Serotonin syndrome risk when co-administered with serotonergic drugs.
1. Cardiovascular risk with IV administration. 2. Suicide risk and behavioral changes. 3. Hepatotoxicity (monitor LFTs). 4. Hematologic effects (agranulocytosis, thrombocytopenia). 5. Lymphadenopathy. 6. Teratogenicity (fetal hydantoin syndrome). 7. Hyperglycemia. 8. Withdrawal seizures. 9. Dermatologic reactions (Stevens-Johnson syndrome). 10. Osteoporosis with chronic use.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity or idiosyncrasy to sympathomimetic amines,Glaucoma,Agitated states,History of drug abuse,During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may occur)
Absolute: Hypersensitivity to phenytoin, hydantoins, or any component; sinus bradycardia, sinoatrial block, second- or third-degree AV block, or Stokes-Adams syndrome (IV formulation); concurrent use with delavirdine. Relative: Pregnancy (especially first trimester; weigh risk vs benefit), hepatic impairment, alcoholism, porphyria.
High-fat meals can delay absorption; avoid acidic foods (e.g., citrus, cola) within 1 hour of dosing as they decrease absorption. Avoid caffeine; may increase stimulant effects.
Avoid grapefruit and grapefruit juice as it inhibits CYP metabolism and can increase phenytoin levels. Enteral feeding formulas may reduce absorption; administer phenytoin 1-2 hours before or after enteral feeds. High doses of folic acid may decrease phenytoin levels. Chronic use can lead to vitamin D and folate deficiency; consider supplementation if indicated. Alcohol consumption should be minimized—acute intake can increase levels while chronic use decreases them.
Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimesters: risk of fetal growth restriction, preterm delivery, and neonatal withdrawal symptoms (irritability, poor feeding).
First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of bleeding disorders in the newborn due to vitamin K deficiency, and potential for neonatal withdrawal and growth restriction.
Excreted into breast milk; relative infant dose estimated at 2-4% of maternal weight-adjusted dose. M/P ratio not well established. Manufacturer recommends caution; potential for infant agitation, insomnia, and growth suppression.
Diphenhydramine is excreted into breast milk in small amounts; reported M/P ratio is approximately 0.5 to 1.0. In infants, risks of drowsiness, irritability, and paradoxical excitation. Generally considered compatible with breastfeeding, but monitor infant for adverse effects.
Increased plasma volume and enhanced hepatic metabolism may reduce amphetamine levels; dose adjustments should be individualized based on clinical response, but controlled studies lacking. Avoid abrupt discontinuation due to risk of withdrawal symptoms in mother and neonate.
No specific dose adjustments are typically required. However, due to increased volume of distribution and metabolism in pregnancy, therapeutic levels may need monitoring. Initial dose adjustments are not recommended, but consider dose increases if clinical response is inadequate.
Adderall 10 mg contains immediate-release amphetamine salts. Onset of action is 30-60 minutes, duration 4-6 hours. Monitor for appetite suppression, insomnia, and cardiovascular effects. Avoid in patients with structural cardiac abnormalities or history of substance abuse. Use with caution in hypertension or hyperthyroidism. Drug holidays may reduce tolerance.
Diphenylan Sodium (phenytoin sodium) is a hydantoin anticonvulsant used for generalized tonic-clonic and complex partial seizures. It exhibits zero-order kinetics at therapeutic levels; small dose increases can cause disproportionate toxicity. Monitor for nystagmus, ataxia, and mental status changes as early signs of toxicity. Due to high protein binding (90%), hypoalbuminemia or uremia increases free fraction—adjust doses based on free phenytoin levels. Can cause folate deficiency, megaloblastic anemia, and bone density loss. Gingival hyperplasia occurs in 40% of patients; meticulous oral hygiene can reduce severity. Dosing must be individualized with therapeutic range 10-20 mg/L total (1-2 mg/L free). Intravenous loading requires cardiac monitoring due to risk of bradycardia and hypotension; avoid IM use due to crystallization and erratic absorption.
Take exactly as prescribed; do not crush or chew tablets.,Take early in the day to prevent insomnia.,May cause weight loss; monitor growth in children.,Avoid alcohol and decongestants (risk of hypertensive crisis).,Report chest pain, palpitations, or shortness of breath immediately.,Do not drive if you feel dizzy or impaired.
Take exactly as prescribed; do not stop abruptly as withdrawal can trigger seizures.,Avoid alcohol and grapefruit juice; they can affect drug levels and increase side effects.,Practice good oral hygiene with regular brushing and flossing to prevent gum overgrowth.,Report any rash, fever, sore throat, or easy bruising immediately—these may signal serious blood disorders.,Use non-hormonal contraception if on birth control; phenytoin reduces efficacy of oral contraceptives.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Wear a medical alert bracelet if you have epilepsy.,Do not take antacids within 2 hours of phenytoin.,Regular blood tests are needed to monitor drug levels and liver function.,If you become pregnant, discuss with your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADDERALL 10 vs DIPHENYLAN SODIUM, answered by our medical review team.
ADDERALL 10 is a CNS Stimulant that works by Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.. DIPHENYLAN SODIUM is a Antiepileptic that works by Phenytoin, the active component, stabilizes neuronal membranes by promoting sodium efflux and inhibiting sodium influx, thereby limiting the spread of seizure activity. It also reduces voltage-gated sodium channel activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADDERALL 10 and DIPHENYLAN SODIUM depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADDERALL 10 is: 10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.. The standard adult dose of DIPHENYLAN SODIUM is: 100 mg orally every 8 hours. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADDERALL 10 and DIPHENYLAN SODIUM in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADDERALL 10 is classified as Category C. Pregnancy Category C. First trimester: potential increased risk of congenital malformations (e.g., gastroschisis, oral clefts) based on limited human data. Second and third trimest. DIPHENYLAN SODIUM is classified as Category C. First trimester: Increased risk of major congenital malformations including neural tube defects, cleft palate, and congenital heart defects. Second and third trimesters: Risks of b. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.